Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07233239 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures

StatusRecruiting
PhasePhase 1
Started2025-11-26
View on ClinicalTrials.gov ↗

Amendment history

2026-08-07
Study Status, Contacts/Locations v12
Study sitesdetails revised at 1 of 24 sites
2026-07-30
Study Status, Contacts/Locations v11
Study sitesdetails revised at 1 of 24 sites
2026-06-05
Study Status, Contacts/Locations v10
Study sitesdetails revised at 1 of 24 sites
2026-06-01
Study Status, Contacts/Locations v9
Study sitesdetails revised at 1 of 24 sites
2026-05-01
Study Status, Contacts/Locations v8
Study sites23→24
Show 7 earlier versions
2026-03-31
Study Status, Eligibility, Contacts/Locations v7
Eligibility criteria+133 characters
[...] izure types with typical interictal/ictal EEG findings (eg, history of an EEG with focal sharp waves or slowing). Participants with a documented diagnosis of focal epilepsy and a normal EEG are eligible for inclusion. Participant is currently treated with at least 1, but no mor [...] in for the duration of the study. Presence of only nonmotor onsetfocal aware seizures or primary generalized epilepsies.
Study sitesdetails revised at 4 of 23 sites
2026-03-06
Study Status, Contacts/Locations v6
Study sitesdetails revised at 1 of 23 sites
2026-02-05
Study Status, Contacts/Locations v5
Study sitesdetails revised at 1 of 23 sites
2025-12-16
Study Status, Contacts/Locations v4
Study sitesdetails revised at 3 of 23 sites
2025-12-05
Study Status, Contacts/Locations v3
Study sitesdetails revised at 1 of 23 sites
2025-12-01
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-12-31→confirmed 2025-11-26
Study sitesdetails revised at 23 of 23 sites
2025-11-20
Study Identification, Study Status, Contacts/Locations v1
Study sites0→23
Study title-34 characters
A Phase 1b, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Cannabidiol Or [...]
2025-11-14
Original filing
Jazz Pharmaceuticals
34 trials monitored
See 1 trial at risk
Epilepsy
723 trials monitored
See 41 trials at risk
Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or Tuberous sclerosis complex (TSC) in patients 1 year of age and older. This study will assess the efficacy and safety of CBD-OS in participants aged 12 to 75 years for the treatment of focal-onset seizures (FOS).
Trial Details
NCT Number NCT07233239
Lead Sponsor Jazz Pharmaceuticals
Collaborators: Jazz Pharmaceuticals Research UK Ltd.
Conditions Focal Seizures
Enrollment 100 participants
Start Date 2025-11-26
Primary Completion 2027-11-29 (estimated)
Study Completion 2027-11-29 (estimated)
Updated on ClinicalTrials.gov 2026-08-11